Design Therapeutics
DSGN
125 hedge funds and large institutions have $404M invested in Design Therapeutics in 2026 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 55 increasing their positions, 29 reducing their positions, and 13 closing their positions.
90% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 29
69% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 13
13% more capital invested
Capital invested by funds: $358M → $404M (+$46.3M)
7% more funds holding
Funds holding: 117 → 125 (+8)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5.37% less ownership
Funds ownership: 66.97% → 61.59% (-5.4%)
Top Buyers
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$15.3M |
| 2 |
TECP
Trails Edge Capital Partners
Atlanta,
Georgia
|
+$8.62M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$5.72M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$3.57M |
| 5 |
Goldman Sachs
New York
|
+$2.37M |
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$26.8M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$5.57M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$4.89M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.31M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$1.66M |
DSGN Hedge Fund Activity: Q1 2026 in Review
125 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q1 2026, worth a combined $404M — up 13% from $358M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new DSGN positions and 13 closed out — a net gain of 9 holders — while 55 added to existing stakes and 29 trimmed.
The largest buyer was RA Capital Management, adding an estimated $15.3M. The largest seller was Point72 Asset Management, cutting an estimated $26.8M.
- 125 institutional investors held Design Therapeutics (DSGN) as of Q1 2026, up from 117 in Q4 2025.
- Funds reported $404M of Design Therapeutics stock for Q1 2026, up 13% quarter-over-quarter.
- 22 funds opened new Design Therapeutics positions in Q1 2026 and 13 closed out, a net change of +9 holders.
- The largest Design Therapeutics buyer in Q1 2026 was RA Capital Management, an estimated $15.3M added.
- The largest Design Therapeutics seller in Q1 2026 was Point72 Asset Management, an estimated $26.8M sold.
Based on aggregated 13F filings for Q1 2026.